News | October 13, 2022
Piramal Pharma Solutions launches ADCelerate
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
The companies will leverage their respective proprietary technology platforms
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
New mass spectrometry instrument and consumables launch during IMSC 2022
The RRA was conducted from 22nd August, 2022 to 26th August, 2022.
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
The WAVEsystem with the WAVEcontrol 4.0 embedded
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
